122 results on '"Avihingsanon A"'
Search Results
2. Urine Xpert Ultra for the Diagnosis of Tuberculosis in People Living with HIV: A Prospective, Multicenter Diagnostic Accuracy Study
3. A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD
4. Outcomes of COVID-19 in kidney transplant recipients in the vaccination Era: A national multicenter cohort from Thailand
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
6. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery
7. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
8. Analyse en sous-groupe de l'efficacité du lénacapavir à la semaine 52 chez les PVVIH lourdement pré-traités
9. Prédicteurs de la réponse au traitement de l'hépatite B chez les personnes coinfectées par le VIH et le VHB
10. Electrochemical capillary-driven microfluidic DNA sensor for HIV-1 and HCV coinfection analysis
11. The Case | Hematuria and hypercalcemia in a kidney transplant recipient
12. WCN23-0493 PREVALENCE OF ARTERIAL STIFFNESS AND ASSOCIATED FACTORS IN THAI HEMODIALYSIS PATIENTS: A CROSS-SECTIONAL MULTICENTER STUDY
13. HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy
14. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis
15. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery
16. The Case | Hematuria and hypercalcemia in a kidney transplant recipient
17. WCN23-0493 PREVALENCE OF ARTERIAL STIFFNESS AND ASSOCIATED FACTORS IN THAI HEMODIALYSIS PATIENTS: A CROSS-SECTIONAL MULTICENTER STUDY
18. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
19. Electrochemical capillary-driven microfluidic DNA sensor for HIV-1 and HCV coinfection analysis
20. Analyse en sous-groupe de l'efficacité du lénacapavir à la semaine 52 chez les PVVIH lourdement pré-traités
21. Prédicteurs de la réponse au traitement de l'hépatite B chez les personnes coinfectées par le VIH et le VHB
22. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
23. HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy
24. An alternative label-free DNA sensor based on the alternating-current electroluminescent device for simultaneous detection of human immunodeficiency virus and hepatitis C co-infection
25. Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study
26. A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISPOT) assay for BK polyomavirus immune response monitoring after kidney transplantation
27. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
28. Performance of a simple flow cytometric assay in diagnosing active tuberculosis
29. Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200 cells/mm3 in Thailand
30. Dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy
31. Gut microbiota composition is difference between HCV mono-infection and HCV/HIV co-infection
32. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic–Pharmacogenetic Model of HIV-infected Patients in Thailand
33. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
34. HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART
35. The challenges of ending AIDS in Asia: outcomes of the Thai National AIDS Universal Coverage Programme, 2000–2014
36. Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network
37. Dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy
38. Efficacy and Safety of Ravidasvir Plus Sofosbuvir in Chronic Hepatitis C Infected Subjects Without Cirrhosis or with Compensated Cirrhosis: Interim Analysis Results of a Two-Stage, Open-Label, Multicentre, Phase 2/3 Trial
39. The occurrence of Simpson's paradox if site-level effect was ignored in the TREAT Asia HIV Observational Database
40. Performance of a simple flow cytometric assay in diagnosing active tuberculosis
41. Gut microbiota composition is difference between HCV mono-infection and HCV/HIV co-infection
42. Efficacy and Safety of Ravidasvir Plus Sofosbuvir in Chronic Hepatitis C Infected Subjects Without Cirrhosis or with Compensated Cirrhosis: Interim Analysis Results of a Two-Stage, Open-Label, Multicentre, Phase 2/3 Trial
43. Atherosclerotic cardiovascular disease screening and management protocols among adult HIV clinics in Asia
44. HBV-related inflammation is linked to the level of genetically intact HIV proviruses
45. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
46. Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand
47. HIV infection of hepatitis B virus (HBV)-infected hepatocytes increases CXCL10 production and is associated with liver fibrosis in HIV-HBV co-infected individuals
48. Immune activation markers associated with levels and diversity of intact HIV proviruses during HIV- HBV co-infection
49. A Case of Very Early Kidney Allograft Dysfunction
50. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.